Artículos por temáticas

Trafficking in neurons: searching for new targets for Alzheimer's disease future therapies

Musardo S, Saraceno C, Pelucchi S, Marcello E.

Eur J Pharmacol. 2013 Nov 5;719(1-3):84-106. doi: 10.1016/j.ejphar.2013.07.019. Epub 2013 Jul 23.

Medication adherence and tolerability of Alzheimer's disease medications: study protocol for a randomized controlled trial

Campbell NL, Dexter P, Perkins AJ, Gao S, Li L, Skaar TC, Frame A, Hendrie HC, Callahan CM, Boustani MA.

Trials. 2013 May 4;14:125. doi: 10.1186/1745-6215-14-125.

Nucleic acid aptamers as novel class of therapeutics to mitigate Alzheimer's disease pathology

Tannenberg RK, Shamaileh HA, Lauridsen LH, Kanwar JR, Dodd PR, Veedu RN.

Curr Alzheimer Res. 2013 May 1;10(4):442-8. doi: 10.2174/1567205011310040009.

A randomized controlled Alzheimer's disease prevention trial's evolution into an exposure trial: the PREADViSE Trial

Kryscio RJ, Abner EL, Schmitt FA, Goodman PJ, Mendiondo M, Caban-Holt A, Dennis BC, Mathews M, Klein EA, Crowley JJ; SELECT Investigators.

J Nutr Health Aging. 2013 Jan;17(1):72-5. doi: 10.1007/s12603-012-0083-3.

From the multifactorial nature of Alzheimer`s disease to multitarget therapy: the contribution of the translational approach

Calzà L, Baldassarro VA, Giuliani A, Lorenzini L, Fernandez M, Mangano C, Sivilia S, Alessandri M, Gusciglio M, Torricella R, Giardino L.

Curr Top Med Chem. 2013;13(15):1843-52. doi: 10.2174/15680266113139990140.

Lessons learnt from glycogen synthase kinase 3 inhibitors development for Alzheimer's disease

Martinez A, Perez DI, Gil C.

Curr Top Med Chem. 2013;13(15):1808-19. doi: 10.2174/15680266113139990138.

Cerebrovascular contributions to Alzheimer's disease pathophysiology and potential therapeutic interventions in mouse models

Thomason LA, Stefanovic B, McLaurin J.

Eur J Neurosci. 2013 Jun;37(12):1994-2004. doi: 10.1111/ejn.12181.

Feasibility, safety and preliminary evidence of the effectiveness of a home-based exercise programme for older people with Alzheimer's disease: a pilot randomized controlled trial

Suttanon P, Hill KD, Said CM, Williams SB, Byrne KN, LoGiudice D, Lautenschlager NT, Dodd KJ.

Clin Rehabil. 2013 May;27(5):427-38. doi: 10.1177/0269215512460877. Epub 2012 Nov 1.

Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors

Bolea I, Gella A, Unzeta M.

J Neural Transm (Vienna). 2013 Jun;120(6):893-902. doi: 10.1007/s00702-012-0948-y. Epub 2012 Dec 13.

Dying other, dying self: creating culture and meaning in palliative healthcare

McCann CJ, Adames HY.

Palliat Support Care. 2013 Aug;11(4):289-93. doi: 10.1017/S1478951512000557. Epub 2012 Aug 1.

Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer's disease

Grossberg G, Cummings J, Frölich L, Bellelli G, Molinuevo JL, Krahnke T, Strohmaier C.

Am J Alzheimers Dis Other Demen. 2013 Sep;28(6):583-91. doi: 10.1177/1533317513495104.

Ingestion of Chlorella reduced the oxidation of erythrocyte membrane lipids in senior Japanese subjects

Miyazawa T, Nakagawa K, Takekoshi H, Higuchi O, Kato S, Kondo M, Kimura F, Miyazawa T.

J Oleo Sci. 2013;62(11):873-81. doi: 10.5650/jos.62.873.

Effect of the timing of acetylcholinesterase inhibitor ingestion on sleep

Song HR, Woo YS, Wang HR, Jun TY, Bahk WM.

Int Clin Psychopharmacol. 2013 Nov;28(6):346-8. doi: 10.1097/YIC.0b013e328364f58d.

Nature as a source of metabolites with cholinesterase-inhibitory activity: an approach to Alzheimer's disease treatment

Pinho BR, Ferreres F, Valentão P, Andrade PB.

J Pharm Pharmacol. 2013 Dec;65(12):1681-700. doi: 10.1111/jphp.12081. Epub 2013 May 16.

A 12-week multidomain intervention versus active control to reduce risk of Alzheimer's disease: study protocol for a randomized controlled trial

Anstey KJ, Bahar-Fuchs A, Herath P, Rebok GW, Cherbuin N.

Trials. 2013 Feb 27;14:60. doi: 10.1186/1745-6215-14-60.